News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
536,201 Results
Type
Article (39233)
Company Profile (82)
Press Release (496886)
Section
Business (151447)
Career Advice (2417)
Deals (27639)
Drug Delivery (92)
Drug Development (72619)
Employer Resources (141)
FDA (13515)
Job Trends (12164)
News (270345)
Policy (26861)
Tag
Academia (2511)
Alliances (38138)
Alzheimer's disease (1294)
Approvals (13474)
Artificial intelligence (150)
Bankruptcy (303)
Best Places to Work (9963)
Breast cancer (190)
Cancer (1410)
Cardiovascular disease (125)
Career advice (2027)
CAR-T (99)
Cell therapy (288)
Clinical research (58378)
Collaboration (475)
Compensation (170)
COVID-19 (2422)
C-suite (141)
Data (1406)
Diabetes (177)
Diagnostics (5542)
Earnings (53432)
Employer resources (129)
Events (73070)
Executive appointments (461)
FDA (14216)
Funding (451)
Gene therapy (208)
GLP-1 (600)
Government (4050)
Healthcare (15945)
Infectious disease (2516)
Inflammatory bowel disease (107)
Interviews (518)
IPO (12415)
Job creations (2576)
Job search strategy (1665)
Layoffs (379)
Legal (5694)
Lung cancer (222)
Manufacturing (180)
Medical device (10472)
Medtech (10476)
Mergers & acquisitions (15447)
Metabolic disorders (471)
Neuroscience (1663)
NextGen: Class of 2025 (5523)
Non-profit (3969)
Northern California (1540)
Obesity (257)
Opinion (189)
Parkinson's disease (103)
Patents (124)
People (50127)
Phase I (17939)
Phase II (25675)
Phase III (19615)
Pipeline (588)
Postmarket research (2309)
Preclinical (7291)
Radiopharmaceuticals (208)
Rare diseases (266)
Real estate (4076)
Regulatory (18573)
Research institute (2105)
Resumes & cover letters (356)
Southern California (1376)
Startups (2718)
United States (13559)
Vaccines (523)
Weight loss (188)
Date
Last 7 days (583)
Last 30 days (1610)
Last 365 days (30157)
2025 (1302)
2024 (30559)
2023 (34095)
2022 (44521)
2021 (47764)
2020 (46283)
2019 (39630)
2018 (30032)
2017 (26941)
2016 (25609)
2015 (29974)
2014 (22438)
2013 (18236)
2012 (19470)
2011 (20494)
2010 (18089)
Location
Africa (714)
Arizona (120)
Asia (33136)
Australia (6937)
California (3477)
Canada (1375)
China (310)
Colorado (159)
Connecticut (157)
Europe (73881)
Florida (521)
Georgia (119)
Illinois (351)
Indiana (212)
Maryland (598)
Massachusetts (2528)
Michigan (163)
Minnesota (230)
New Jersey (1013)
New York (1008)
North Carolina (629)
Northern California (1540)
Ohio (124)
Pennsylvania (802)
South America (984)
Southern California (1376)
Texas (515)
Utah (114)
Washington State (362)
536,201 Results for "bioohio formerly known as omeris".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope
January 7, 2025
·
1 min read
BioMidwest
New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
Baxter International Inc. announced new data showing expanded hemodialysis, known as HDx therapy, enabled by Theranova dialyzer, was associated with an approximately 25% lower all-cause mortality risk for up to four years when compared to high-flux hemodialysis.
May 29, 2024
·
5 min read
Spur Therapeutics (Formerly Freeline) Announces New Name and Brand
Spur Therapeutics, formerly Freeline Therapeutics, today announced a new name and brand to reflect its focus on developing a new generation of gene therapies and advancing the practice of genetic medicine.
June 17, 2024
·
5 min read
Immunology and inflammation
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
January 13, 2025
·
2 min read
·
Tristan Manalac
Drug Development
AltruBio Raises $225M in Series B to Advance Ulcerative Colitis Candidate
Formerly known as AbGenomics Holding, AltruBio on Tuesday said it will use the funds to push its ulcerative colitis asset into a Phase IIb trial with an anticipated readout in 2026.
May 21, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Parabilis Medicines™ – Formerly FogPharma – Announces New Company Name and Unveils AI- and Physics-Based Discovery Platform
October 28, 2024
·
3 min read
Drug Development
89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis
89bio, Inc. today announced the initiation of its Phase 3 ENLIGHTEN Program evaluating the efficacy and safety of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).
March 12, 2024
·
8 min read
FDA
Association for Diagnostics & Laboratory Medicine (formerly AACC) files an amicus brief backing the American Clinical Laboratory Association’s lawsuit against the FDA
October 7, 2024
·
5 min read
Press Releases
New SELECT trial analysis with semaglutide 2.4 mg showed a significant reduction in hospital admissions in adults with known heart disease and obesity or overweight
November 4, 2024
·
6 min read
Business
Medivir’s partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
Medivir AB announced today that its partner Vetbiolix, a veterinary biotechnology company based in France , reported positive results from a Proof-of-Concept clinical study in periodontal disease in dog with its drug candidate VBX-1000, previously known as MIV-701.
April 15, 2024
·
3 min read
1 of 53,621
Next
